



AI-driven efficient prescribing assistance

## About Posos

Founded in 2018, Posos is a MedTech company that has built the world's most advanced artificial intelligence platform dedicated to medical prescriptions. It seamlessly integrates into a hospital's electronic medical records, enabling healthcare prescribers to use AI to prescribe in real-time, based on the best recommendations. Co-created by Posos' pharmacists and engineers, the platform has received approval from health authorities in France. Its powerful AI assistant speeds up and optimizes the prescribing process, which is currently very time-consuming and approximate within EHR. Posos can drive massive patient and economic impact, as demonstrated by the numerous EU institutions that have already adopted the solution.

## Posos in Numbers

- Posos has 40 employees
- Posos has 85,000 users among healthcare professionals, including 35,000 physicians in 5 countries.
- Since its creation, Posos has raised 11.8 million euros
- Posos is a Medical Device with CE marking
- Posos is embedded in top EU EHR/EMR software: DxCare, Softway, Bow Medical and Evolucare, among others.
- Contact us: [www.posos.ai](http://www.posos.ai)

## Making intelligent prescription easy

Posos' innovative technology for transcribing and securing prescriptions makes patient care safer and more efficient. It can:

- Import a complex medical prescription, whether voice-dictated on a smartphone or via a script photo, directly into the patient's records in a structured data stream (FHIR).
- Identify and prioritize patient risks according to the patient profile.
- Formulate drug management recommendations based on the latest medical references, adapting them to the patient's profile to guarantee the best treatment.
- Accelerate the drug reconciliation process while reviewing all the patient's treatments from admission to hospital discharge in order to correct iatrogenic errors.

**2018**

Founded by Emmanuel Bilbault and Benjamin Grelié

**2019**

Fundraising of 2M euros

**2021**

Posos is used by 40,000 practitioners

**2022**

Series A fundraising of 9.8M euros

**2023**

Launch of Posos' proprietary drug database, the only DB fully encoded in international terminologies and interoperable

Obtained French Health Authority's certification



AI-driven efficient prescribing assistance

## Proprietary AI-built drug database

After two years of R&D development, Posos, an AI prescription tool, has developed a new-generation drug database.

Uniquely crafted by AI algorithms and a team of skilled pharmacists, the Posos Medical Database is natively multilingual, encoded in SNOMED terminologies, and seamlessly interoperable.

This database effortlessly integrates into any medical software worldwide, offering healthcare providers a comprehensive prescription assistance solution. Healthcare providers finally have reliable, finely structured data, designed to be seamlessly cross-referenced with all types of patient data. This minimizes irrelevant alerts and facilitates the prescription of the most effective therapeutic solutions for each patient, no matter how complex their current medical care is.

## Iatrogeny figure

- In the United States, medication errors are estimated to harm 1.3 million people every year, and are responsible for a large number of preventable deaths. (WHO)
- In 2022, the French Health Authority (Haute autorité de santé) recorded a concerning increase of around 2,400 serious adverse events related to medical care in France during hospitalization.
- Over the past six years, medication dosage errors have accounted for 44% of all reported medication errors. (HAS)

## In a nutshell

Posos enables safe and efficient care through innovation with its secure prescription transcription technology. To improve the quality of care and take medicine to new, higher standards, Posos provides caregivers with a responsible medical AI. The aim is to enable caregivers to free themselves from low-value-added tasks, in favor of human care and support.

Posos' mission is to improve the therapeutic management of patients and help reduce the risk of drug-related iatrogeny on an international scale.

